Literature DB >> 26909486

Reciprocal changes of serum adispin and visfatin levels in patients with type 2 diabetes after an overnight fast.

Ioannis Legakis1, Timos Mantzouridis2, George Bouboulis3, George P Chrousos4.   

Abstract

OBJECTIVE: In order to elucidate the interrelationship of adipokines in glucose hemiostasis, we determined the concentration of visfatin and adipsin in blood samples in patients with type 2 diabetes and age-matched controls after an overnight fast. SUBJECTS AND METHODS: We enrolled 37 patients with known type 2 diabetes -21 males and 16 females, aged 62.95 ± 15.72 years and 43 controls- 28 males and 15 females, aged 60.79 ± 12.67 years. Blood samples were collected after an overnight fast and routine biochemical parameters such as glucose, cholesterol, HDL, LDL, triglycerides along with Hb1Ac, insulin and c-peptide, in addition to circulating visfatin and adipsin were determined in all samples. Data were considered significant at a level of p < 0.05.
RESULTS: In patients with type 2 diabetes, circulating adipsin levels were decreased and inversely related with glucose levels while circulating visfatin was increased significantly in the fasting state.
CONCLUSION: These results implicate the adipokines adipsin and visfatin as possible participants in the pathogenesis of type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26909486     DOI: 10.1590/2359-3997000000147

Source DB:  PubMed          Journal:  Arch Endocrinol Metab        ISSN: 2359-3997            Impact factor:   2.309


  8 in total

1.  Soluble EGFR, a hepatokine, and adipsin, an adipokine, are biomarkers correlated with distinct aspects of insulin resistance in type 2 diabetes subjects.

Authors:  Mayu Kyohara; Jun Shirakawa; Tomoko Okuyama; Yu Togashi; Ryota Inoue; Jinghe Li; Daisuke Miyashita; Yasuo Terauchi
Journal:  Diabetol Metab Syndr       Date:  2020-09-29       Impact factor: 3.320

2.  The role of production of adipsin and leptin in the development of insulin resistance in patients with abdominal obesity.

Authors:  M A Vasilenko; E V Kirienkova; D A Skuratovskaia; P A Zatolokin; N I Mironyuk; L S Litvinova
Journal:  Dokl Biochem Biophys       Date:  2017-09-02       Impact factor: 0.788

3.  Anthocyanins regulate serum adipsin and visfatin in patients with prediabetes or newly diagnosed diabetes: a randomized controlled trial.

Authors:  Liping Yang; Yun Qiu; Wenhua Ling; Zhaomin Liu; Lili Yang; Changyi Wang; Xiaolin Peng; Li Wang; Jianying Chen
Journal:  Eur J Nutr       Date:  2020-09-15       Impact factor: 5.614

4.  Risk factors associated with the progression and metastases of hindgut neuroendocrine tumors: a retrospective study.

Authors:  Yoichiro Okubo; Rika Kasajima; Masaki Suzuki; Yohei Miyagi; Osamu Motohashi; Manabu Shiozawa; Emi Yoshioka; Kota Washimi; Kae Kawachi; Yoichi Kameda; Tomoyuki Yokose
Journal:  BMC Cancer       Date:  2017-11-16       Impact factor: 4.430

5.  Relationship between serum adipsin and the first phase of glucose-stimulated insulin secretion in individuals with different glucose tolerance.

Authors:  Qing Zhou; Qian Ge; Yao Ding; Hua Qu; Huili Wei; Rui Wu; Lu Yao; Qianping Wei; Zhengping Feng; Jian Long; Huacong Deng
Journal:  J Diabetes Investig       Date:  2018-03-22       Impact factor: 4.232

6.  Association of circulating adipsin with nonalcoholic fatty liver disease in obese adults: a cross-sectional study.

Authors:  Jinhua Zhang; Kangli Li; Lingling Pan; Fei Teng; Peizhen Zhang; Bingquan Lin; Youwen Yuan; Xueyun Wei; Wenyuan Li; Huijie Zhang
Journal:  BMC Gastroenterol       Date:  2021-03-21       Impact factor: 3.067

Review 7.  Plasma Adipsin as a Biomarker and Its Implication in Type 2 Diabetes Mellitus.

Authors:  Gebrehiwot Gebremedhin Tafere; Dawit Zewdu Wondafrash; Kaleab Alemayehu Zewdie; Brhane Teklebrhan Assefa; Muluken Altaye Ayza
Journal:  Diabetes Metab Syndr Obes       Date:  2020-05-28       Impact factor: 3.168

8.  Circulating adipsin is associated with asymptomatic carotid atherosclerosis in obese adults.

Authors:  Jinhua Zhang; Fei Teng; Lingling Pan; Dan Guo; Jianfang Liu; Kangli Li; Youwen Yuan; Wenyuan Li; Huijie Zhang
Journal:  BMC Cardiovasc Disord       Date:  2021-10-25       Impact factor: 2.298

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.